To the Editor:

Mykén and Bech-Hansen\(^1\) reported a 20-year experience with the Biocor valve (St Jude Medical, Inc, St Paul, Minn). This study consisted of 1518 aortic valve replacements and 194 mitral valve replacements (MVRs). The predominant area of interest in the report has been the durability of the prosthesis in the mitral position. The article reported on structural valve deterioration (SVD) as determined by explant reoperation. The alternative method of retrospective reporting is to combine SVD by explant reoperation and with SVD by clinical (echocardiographic) evaluation. Mykén and Bech-Hansen\(^1\) reported echocardiographic performance but did not include echocardiographic evaluation in their durability analysis. Only Kaplan–Meier actuarial data analysis was reported, because their objective was to report on prosthetic performance and not performance in a specific population subset (actual cumulative incidence).

Mykén and Bech-Hansen\(^1\) reported promising results with respect to MVR actuarial freedom from explant reoperation for SVD. For patients older than 65 years, the 20-year actuarial freedom from reoperation for SVD in MVR was 88.0%. Two previous reports on MVR freedom from reoperative SVD have illustrated similar results, noting highly satisfactory 15-year durability performance in MVR populations with mean ages of 48 and 49 years.\(^2,3\) Pomerantzeff and colleagues\(^3\) in 2006 reported favorable actuarial freedoms from reoperation for SVD for MVR at 15 years of 88.7% for patients 51 to 60 years old and 84% for patients 61 to 80 years old. Kirali and colleagues\(^2\) reported in 2001 MVR actuarial freedom from reoperation for SVD of 76.8% at 13 years. An important aspect of the latter publication is that the freedom from SVD for all clinically documented cases was 64.8% at 13 years (39 cases of overall SVD vs 16 reoperative cases). The distinctions in reporting of SVD for MVR by the different definitions are illustrated by Kirali and colleagues.\(^2\)

Mykén and Bech-Hansen\(^1\) reported that for patients older than 65 years undergoing aortic valve replacement the 20-year actuarial freedom from reoperation for SVD was 92.1%. In 2008, Eichinger and coauthors,\(^4\) in a separate 20-year publication on the Biocor prosthesis, reported actuarial freedom from reoperation for SVD at 15 years of 90.6% for aortic valve replacement in a cohort of 455 patients (mean age, 72.5 \pm 9 years). The actuarial freedom at 15 years for overall SVD was 85.4%. Sixteen of 23 patients with SVD came to reoperation. The actuarial freedom at 20 years from reoperation for SVD was 86.5%. The distinctions in reporting of SVD for aortic valve replacement by the different definitions are illustrated by Eichinger and colleagues.\(^4\)

The comparison of SVDs from various studies must always consider how SVD is reported, either on the basis of explant reoperation or on the basis of a combination of explant reoperation and clinical parameters. The currently approved next generation of the Biocor porcine bioprosthesis, the Epic porcine bioprosthesis, needs durability assessment, preferably combining both methods of reporting SVD, by reoperation explant and by reoperation explant combined with clinical (echo-cardiographic) evaluation.

W. R. Eric Jamieson, MD
Department of Surgery
University of British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada

References

Replay to the Editor:

We thank Drs Suyker and Leicher for their comments\(^1\) regarding our article reporting 20-year experience of 1712 patients with the Biocor (St Jude Medical, Inc, Minneapolis, Minn) porcine bioprosthesis\(^2\) and would like to respond. We agree that one would wish for longer mean follow-up; however, our study does not differ significantly from other 20-year studies (Table 1).\(^3,8\) This only reflects the increasing numbers of bioprostheses inserted during this period, a trend for the entire Western world.

Suyker and Leicher\(^1\) are further concerned that reporting actuarial freedom from reoperation for structural valve deterioration (SVD) rather than all SVD may underestimate the impact of SVD. The difficulty is that there is no specific definition of SVD. All bioprostheses are gradually degenerating, and which valves should categorize as affected by SVD? Even if we had a consensus definition, there is difficulty in obtaining

---

The Editor welcomes submissions for possible publication in the Letters to the Editor section that consist of commentary on an article published in the Journal or other relevant issues. Authors should: • Include no more than 500 words of text, three authors, and five references. • Type with double-spacing. • See http://jtcvs.ctsnetjournals.org/misc/ifora.shtml for detailed submission instructions. • Submit the letter electronically via jtcvs.editorialmanager.com.

Letters commenting on an article published in the JTCVS will be considered if they are received within 6 weeks of the time the article was published. Authors of the article being double-spaced on will be given an opportunity of offer a timely response (2 weeks) to the letter. Authors of letters will be notified that the letter has been received. Unpublished letters cannot be returned.